CL King initiated coverage of Integra LifeSciences with a Buy rating and $50 price target. The firm believes the stock price is currently depressed due to the Boston recall and FDA Warning Letter, but as the company proceeds with its remediation plans, the stock price should move higher, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences price target lowered to $39 from $41 at Truist
- Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo
- Integra LifeSciences sees Q4 adjusted EPS 89c-93c, consensus 92c
- Integra LifeSciences narrows FY23 EPS view to $3.10-$3.14 from $3.10-$3.18
- Integra LifeSciences reports Q3 adjusted EPS 76c, consensus 78c